200,000+ products from a single source!

sales@angenechem.com

Home > Other Building Blocks > 95041-90-0

95041-90-0

95041-90-0 | 2-Methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol

CAS No: 95041-90-0 Catalog No: AG003A3K MDL No:MFCD06795132

Product Description

Catalog Number:
AG003A3K
Chemical Name:
2-Methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
CAS Number:
95041-90-0
Molecular Formula:
C18H22O5
Molecular Weight:
318.3643
MDL Number:
MFCD06795132
IUPAC Name:
2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
InChI:
InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h7-11,19H,5-6H2,1-4H3
InChI Key:
UXDFUVFNIAJEGM-UHFFFAOYSA-N
SMILES:
COc1cc(CCc2ccc(c(c2)O)OC)cc(c1OC)OC
NSC Number:
613744

Properties

Complexity:
323  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
318.147g/mol
Formal Charge:
0
Heavy Atom Count:
23  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
318.369g/mol
Monoisotopic Mass:
318.147g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
57.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.7  

Literature

Title Journal
Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: synthesis, cytotoxicity and antitubulin activity. European journal of medicinal chemistry 20120601
Discovery of isoerianin analogues as promising anticancer agents. ChemMedChem 20110307
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4. European journal of medicinal chemistry 20090601
Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells. In vivo (Athens, Greece) 20040101
Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorganic & medicinal chemistry letters 20010108

© 2019 Angene International Limited. All rights Reserved.